Pre-eclampsia Pregnancy and Childbirth Pre-eclampsia, unspecified
Conditions
Interventions
Two treatment groups: 60 mcg/day of selenium as selenium-enriched yeast or placebo yeast (60 mcg/day is the recommended intake for UK pregnant women).
Total duration of intervention: From randomisati
Sponsors
University of Surrey (UK)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. First pregnancy 2. 12-14 weeks pregnant at randomisation
Exclusion criteria
Exclusion criteria: 1. Under 18 years old 2. Current smokers (who have lower risk of pre-eclampsia) 3. Taking any supplement containing Se 4. Taking thyroid medication 5. Multiple pregnancy 6. Abnormal fetal anomaly scan 7. Chronic proteinuria 8. Heparin treatment 9. Human immunodeficiency virus (HIV), Hep-B or Hep-C positive 10. Yeast intolerance (supplement contains yeast)# 11. inability or refusal to give informed consent (the genetic component of the trial will be omitted in those who do not give explicit consent to this aspect of the trial)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma soluble fms-like tyrosine kinase-1 (sFlt-1) concentration. Measured in samples taken at 35 weeks gestation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Plasma concentrations of: placental growth factor (PlGF), sEndoglin, ActivinA, InhibinA, E-selectin, vascular cell adhesion molecule 1 (VCAM-1), 3-Nitrotyrosine, Pentraxin 3, C-reactive protein (CRP). Measured in samples taken at 35 weeks gestation. | — |
Countries
United Kingdom
Outcome results
None listed